Prognosis for patients with metastatic breast cancer who achieve a no-evidence-of-disease status after systemic or local therapy

Cancer
Andrew J BishopWendy A Woodward

Abstract

This study sought to determine outcomes for patients with metastatic breast cancer (MBC) with no evidence of disease (NED) after treatment and to identify factors predictive of outcomes once the status of NED was attained. This study reviewed 570 patients with MBC who were consecutively treated between January 2003 and December 2005. Ninety patients (16%) attained NED, which was defined as a complete metabolic response on positron emission tomography or sclerotic healing of bone metastases on computed tomography or magnetic resonance imaging. The median follow-up for patients attaining NED was 100 months (range, 14-134 months). The 3- and 5-year overall survival (OS) rates were 44% and 24%, respectively, for the entire group and 96% and 78%, respectively, for those attaining NED. According to a landmark analysis, NED status was significantly associated with survival at 2 (P < .001; hazard ratio [HR], 0.23; 95% confidence interval [CI], 0.16-0.34) and 3 years (P < .001; HR, 0.20; 95% CI, 0.14-0.30). From the time of NED, the median survival was 102 months (range, 14-134 months) with 5-year OS and progression-free survival (PFS) rates of 77% and 40%, respectively. According to a multivariate analysis, human epidermal growth facto...Continue Reading

References

Aug 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P A GreenbergA U Buzdar
Feb 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gabriel N Hortobagyi
Dec 24, 2003·Cancer·Sharon H GiordanoGabriel N Hortobagyi
Feb 19, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Rebecca G HagertyMartin H N Tattersall
Aug 30, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Shaheenah DawoodSharon H Giordano
Oct 28, 2008·Palliative Medicine·S Innes, S Payne
Mar 25, 2009·Nature Reviews. Cancer·Don X NguyenJoan Massagué
Mar 12, 2010·Journal of the National Cancer Institute·Olivia PaganiUNKNOWN ESO-MBC Task Force
Apr 30, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S DawoodS H Giordano
Dec 30, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Belinda E KielyMartin R Stockler
Apr 6, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alessandra GennariPaolo Bruzzi
May 14, 2011·Breast Cancer : the Journal of the Japanese Breast Cancer Society·Yee Chung Cheng, Naoto T Ueno
Nov 2, 2013·Therapeutic Advances in Medical Oncology·Raffaella PalumboAntonio Bernardo

❮ Previous
Next ❯

Citations

Sep 28, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S T ButterbaughA Mathew
Sep 8, 2019·Breast Cancer Research and Treatment·T G SteenbruggenG S Sonke
Oct 13, 2018·Journal of the National Cancer Institute·Elisabeth TrappUNKNOWN SUCCESS Study Group
Jan 7, 2017·Breast Cancer : the Journal of the Japanese Breast Cancer Society·Giulia GalliSerena Di Cosimo
Jan 8, 2020·Reports of Practical Oncology and Radiotherapy : Journal of Greatpoland Cancer Center in Poznań and Polish Society of Radiation Oncology·Marta BonetUNKNOWN Grup Oncològic Català Occità (GOCO Group)

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Ductal

Ductal carcinoma is a malignant neoplasm involving the ductal systems of any of a number of organs, such as the mammary glands, pancreas, prostate or lacrimal gland. Discover the latest research on ductal carcinoma here.

Carcinoma, Lobular

Lobular carcinoma is an invasive type of breast cancer in which lobules, areas of the breast that produce milk, undergo malignant transformation. Here is the latest research.